Abstract

BackgroundHemorrhagic transformation (HT) is a critical issue in thrombolytic therapy in acute ischemic stroke. Damage-associated molecular pattern (DAMP)-stimulated sterile neuroinflammation plays a crucial role in the development of thrombolysis-associated HT. Our previous study showed that the phthalide derivative CD21 attenuated neuroinflammation and brain injury in rodent models of ischemic stroke. The present study explored the effects and underlying mechanism of action of CD21 on tissue plasminogen activator (tPA)-induced HT in a mouse model of transient middle cerebral artery occlusion (tMCAO) and cultured primary microglial cells.MethodsThe tMCAO model was induced by 2 h occlusion of the left middle cerebral artery with polylysine-coated sutures in wildtype (WT) mice and macrophage scavenger receptor 1 knockout (MSR1−/−) mice. At the onset of reperfusion, tPA (10 mg/kg) was intravenously administered within 30 min, followed by an intravenous injection of CD21 (13.79 mg/kg/day). Neuropathological changes were detected in mice 3 days after surgery. The effect of CD21 on phagocytosis of the DAMP peroxiredoxin 1 (Prx1) in lysosomes was observed in cultured primary microglial cells from brain tissues of WT and MSR1−/− mice.ResultsSeventy-two hours after brain ischemia, CD21 significantly attenuated neurobehavioral dysfunction and infarct volume. The tPA-infused group exhibited more severe brain dysfunction and hemorrhage. Compared with tPA alone, combined treatment with tPA and CD21 significantly attenuated ischemic brain injury and hemorrhage. Combined treatment significantly decreased Evans blue extravasation, matrix metalloproteinase 9 expression and activity, extracellular Prx1 content, proinflammatory cytokine mRNA levels, glial cells, and Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB) pathway activation and increased the expression of tight junction proteins (zonula occludens-1 and claudin-5), V-maf musculoaponeurotic fibrosarcoma oncogene homolog B, and MSR1. MSR1 knockout significantly abolished the protective effect of CD21 against tPA-induced HT in tMCAO mice. Moreover, the CD21-induced phagocytosis of Prx1 was MSR1-dependent in cultured primary microglial cells from WT and MSR1−/− mice, respectively.ConclusionThe phthalide derivative CD21 attenuated tPA-induced HT in acute ischemic stroke by promoting MSR1-induced DAMP (Prx1) clearance and inhibition of the TLR4/NF-κB pathway and neuroinflammation.

Highlights

  • Hemorrhagic transformation (HT) is a critical issue in thrombolytic therapy in acute ischemic stroke

  • The present findings demonstrated the involvement of the Damage-associated molecular pattern (DAMP) peroxiredoxin 1 (Prx1) in tissue plasminogen activator (tPA)-induced blood-brain barrier (BBB) dysfunction and HT after brain ischemia, which were significantly ameliorated by CD21 through the upregulation of MSR1promoted DAMP (Prx1) clearance and inhibition of Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB) in transient middle cerebral artery occlusion (tMCAO) mice and cultured primary microglial cells

  • We found that tPA upregulated MMP-9 immunoreactivity and activity in the ischemic brain (p < 0.05 and p < 0.01, respectively, vs. tMCAO group), which was inhibited by combined treatment with tPA and CD21 (p < 0.05 and p < 0.01, respectively, vs. tPA group; Fig. 2d–f)

Read more

Summary

Introduction

Hemorrhagic transformation (HT) is a critical issue in thrombolytic therapy in acute ischemic stroke. Thrombolysis with tissue plasminogen activator (tPA) to restore blood supply to the ischemic area has been widely used for the clinical treatment of acute ischemic stroke [2]. This revascularization therapy, has a narrow therapeutic time window (3–4.5 h), which greatly limits its clinical utility [3]. Many patients suffer from severe side effects, hemorrhagic transformation (HT), after thrombolysis with tPA [2, 3] This cerebral HT results in a worse clinical prognosis and even death in ischemic stroke patients who receive tPA treatment. Strategies that can ameliorate tPA-related HT would significantly improve clinical thrombolytic treatment outcomes

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.